Form 8-K AbbVie Inc. For: Feb 02

Go back to Form 8-K AbbVie Inc. For: Feb 02

Abbvie (ABBV) PT Raised to $154 at BMO Capital

February 3, 2022 7:19 AM EST

BMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $154.00 (from $153.00) while maintaining an Outperform rating.

The analyst commented, "4Q good overall despite slight revenue shortfall as many key growth drivers performed well and better op. leverage drove EPS... More